Opportunities for therapeutic antibodies directed at G-protein-coupled receptors
Nature Reviews Drug Discovery 16, 661 (2017).
doi:10.1038/nrd.2017.173
Author: Catherine J. Hutchings, Markus Koglin, William C. Olson & Fiona H. Marshall
Nature Reviews Drug Discovery16 (2017)In the article, the clinical trial for the biparatopic CXCR2 nanobody was described as being for cancer instead of inflammation. This error has been corrected in the online version.
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Catherine J. Hutchings Markus Koglin William C. Olson Fiona H. Marshall Tags: Corrigendum Source Type: research